The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Open accessAbstract
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and the leading cause of chronic liver disease in the Western world. Twenty per cent of NAFLD individuals develop chronic hepatic inflammation (non-alcoholic steatohepatitis, NASH) associated with cirrhosis, portal hypertension and hepatocellular carcinoma, yet the causes of progression from NAFLD to NASH remain obscure. Here, we show that the NLRP6 and NLRP3 inflammasomes and the effector protein IL-18 negatively regulate NAFLD/NASH progression, as well as multiple aspects of metabolic syndrome via modulation of the gut microbiota. Different mouse models reveal that inflammasome-deficiency-associated changes in the configuration of the gut microbiota are associated with exacerbated hepatic steatosis and inflammation through influx of TLR4 and TLR9 agonists into the portal circulation, leading to enhanced hepatic tumour-necrosis factor (TNF)-α expression that drives NASH progression. Furthermore, co-housing of inflammasome-deficient mice with wild-type mice results in exacerbation of hepatic steatosis and obesity. Thus, altered interactions between the gut microbiota and the host, produced by defective NLRP3 and NLRP6 inflammasome sensing, may govern the rate of progression of multiple metabolic syndrome-associated abnormalities, highlighting the central role of the microbiota in the pathogenesis of heretofore seemingly unrelated systemic auto-inflammatory and metabolic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Either in patients with NASH or animal models, the expression of inflammasome components was increased, indicating the potential role in the pathogenesis of liver injury [226,227,288,289,290,291].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [226]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LPS-mediated activation of KCs via TLR4 leading to MyD88-dependent activation of NF-kB, production of proinflammatory cytokines and subsequent liver injury have also been demonstrated for both MASH(214) and ASH(215).”
From The liver as a central "hub" of the immune system: pathophysiological implications (2025) · cites this paper as [214]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Animal studies have demonstrated a direct role of altered intestinal microbiota in steatosis,15 NASH(16), fibrosis17 and liver cancer.18”
From Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling (2023) · cites this paper as [16]
In the citing paper
“In NAFLD models, lack of inflammasomes has been demonstrated to select a pathogenetic microbiota which was associated with a more severe degree of liver injury [226].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [226]
In the citing paper
“These results indicate that complex interactions between the diet, the innate immunity, bacteria and intestinal function occurs in the development of NASH [226,227], and similar observations were obtained in experimental models of HCC development [285,286,287].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [226]
In the citing paper
“Co-housing wildtype mice with mice prone to MASH led to increased disease severity in wildtype mice, presumably due to a transfer of fecal microbiota (204).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [204]
In the citing paper
“In the MCD diet model, the microbiota has a key role in NASH exacerbation as demonstrated by experiments, in which co-housing transmitted NASH risk and antibiotics reduced NASH risk65.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [65]
In the citing paper
“Functional studies utilizing co-housing and faecal transplantation have provided evidence that dysbiosis is a transmissible driver of liver disease development and progression 65,89.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [65]
In the citing paper
“Similarly, dysbiosis represented a transmissible risk factor in a genetic NASH model in which NASH was triggered by inflammasome deficiency; co-housing of dysbiotic inflammasome-deficient mice with control mice resulted in the development of NASH in control mice65.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [65]
In the citing paper
“Association of bacterial composition with many diseases has been observed, including immune, inflammatory, and metabolic phenotypes.”
From The Gut Microbiome Contributes to a Substantial Proportion of the Variation in Blood Lipids (2015) · cites this paper as [5]
In the citing paper
“Disruption of the murine inflammasomes (see box 1) is associated with an increase in Bacteroidetes and reduction in Firmicutes and results in severe hepatic steatosis and inflammation.41”
From The gut microbiota and host health: a new clinical frontier (2016) · cites this paper as [41]
In the citing paper
“the NLRP6 and NLRP3 inflammasomes may exert protective effects against NAFLD/NASH through modulation of the gut microbiota.181”
From Interaction between microbiota and immunity in health and disease (2020) · cites this paper as [181]
In the citing paper
“Dysbiosis has been observed in mice deficient for inflammasomes components, including NLRP6, ASC, caspase-1, and IL-18 [131,132,133,134].”
From Gut Microbiota and Cancer: From Pathogenesis to Therapy (2019) · cites this paper as [134]
In the citing paper
“The Muc2-KO mouse possesses a distinct gut-associated bacterial community that is influenced by its altered genetic and immune states, as has been shown in other genetic knockout mouse models.4,53–55”
From Using Corticosteroids to Reshape the Gut Microbiome: Implications for Inflammatory Bowel Diseases (2015) · cites this paper as [54]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
QIIME allows analysis of high-throughput community sequencing data
Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Peña, A. G., Goodrich, J. K., Gordon, J. I., et al. (2010) · Nature Methods · doi:10.1038/nmeth.f.303 · Cited by 34,887
Self-citationDesign and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
A Toll-like receptor recognizes bacterial DNA
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491 · cited 1×
“Tlr9 –/– mice have been described in another repor”
BackgroundMartinon, F., Burns, K., & Tschopp, J. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00599-3 · Cited by 6,066
A role for mitochondria in nlrp3 inflammasome activation
Zhou, R., Yazdi, A. S., Menu, P., & Tschopp, J. (2011) · Nature · doi:10.1038/nature09663 · Cited by 5,602
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50161 · Cited by 2,728
Thioredoxin-interacting protein links oxidative stress to inflammasome activation
Zhou, R., Tardivel, A., Thorens, B., Choi, I., & Tschopp, J. (2010) · Nature Immunology · doi:10.1038/ni.1831 · Cited by 2,708
Cited by
Sorted by citations
Items 901–1,000 of 1,011
Flores-Guerrero, J. L., Post, A., van Dijk, P. R., Connelly, M. A., Garcia, E., Navis, G. J., Bakker, S. J. L., & Dullaart, R. P. F. (2021) · Liver International · doi:10.1111/liv.14963 · Cited by 60
The liver as a central "hub" of the immune system: pathophysiological implications
Ronca, V., Gerussi, A., Collins, P., Parente, A., Oo, Y. H., & Invernizzi, P. (2025) · Physiological Reviews · doi:10.1152/physrev.00004.2023 · Cited by 59
Sanduzzi‐Zamparelli, M., Compare, D., Coccoli, P., Rocco, A., Nardone, O. M., Marrone, G., Gasbarrini, A., Grieco, A., Nardone, G., & Miele, L. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17081225 · Cited by 64
Microbiome: A forgotten target of environmental micro(nano)plastics?
Santos, A. L., Rodrigues, C. C., Oliveira, M., & Rocha, T. L. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.153628 · Cited by 61
Gut microbiome therapy: fecal microbiota transplantation vs live biotherapeutic products
Kim, D.-Y., Lee, S.-Y., Lee, J., Whon, T. W., Lee, J., Jeon, C. O., & Bae, J. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2412376 · Cited by 62
Hygiene and Other Early Childhood Influences on the Subsequent Function of the Immune System
Rook, G. A. W. (2011) · Digestive Diseases · doi:10.1159/000323877 · Cited by 60
Energy intake, metabolic homeostasis, and human health
Pang, G., Xie, J., Chen, Q., & Zhi-he, H. (2014) · Food Science and Human Wellness · doi:10.1016/j.fshw.2015.01.001 · Cited by 64
Sagawa, H., Naiki‐Ito, A., Kato, H., Naiki, T., Yamashita, Y., Suzuki, S., Sato, S., Shiomi, K., Kato, A., Kuno, T., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv143 · Cited by 61
Agosti, P., Sabbà, C., & Mazzocca, A. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.11.026 · Cited by 59
The Biological Clock: A Pivotal Hub in Non-alcoholic Fatty Liver Disease Pathogenesis
Mazzoccoli, G., Cosmo, S. D., & Mazza, T. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00193 · Cited by 62
Potential mechanisms linking gut microbiota and portal hypertension
Baffy, G. (2018) · Liver International · doi:10.1111/liv.13986 · Cited by 59
Hua, P., Yu, Z., Xiong, Y. C., Liu, B., & Zhao, L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19124023 · Cited by 61
Microbiota-Propelled T Helper 17 Cells in Inflammatory Diseases and Cancer
Bellone, M., Brevi, A., & Huber, S. (2020) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00064-19 · Cited by 60
Krautkramer, K. A., Dhillon, R. S., Denu, J. M., & Carey, H. V. (2017) · Translational research · doi:10.1016/j.trsl.2017.08.005 · Cited by 61
Zhao, H., Gao, X., Liu, Z., Zhang, L., Fang, X., Sun, J., Zhang, Z., & Sun, Y. (2022) · Nutrients · doi:10.3390/nu14224846 · Cited by 58
The Gut-Prostate Axis: A New Perspective of Prostate Cancer Biology through the Gut Microbiome
Fujita, K., Matsushita, M., Velasco, M. A. D., Hatano, K., Minami, T., Nonomura, N., & Uemura, H. (2023) · Cancers · doi:10.3390/cancers15051375 · Cited by 62
The Multifaceted Role of Commensal Microbiota in Homeostasis and Gastrointestinal Diseases
Silva, M. J. B., Carneiro, M. B. H., Pultz, B. D. A., Silva, D. P., Lopes, M. E., & dos Santos, L. M. (2015) · Journal of Immunology Research · doi:10.1155/2015/321241 · Cited by 61
Chemoprevention in Gastrointestinal Physiology and Disease. Natural products and microbiome
Greiner, A. K., Papineni, R. V. L., & Umar, S. (2014) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00044.2014 · Cited by 60
Convergent pathways that cause hepatic fibrosis in NASH
Friedman, S. L. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.256 · Cited by 58
Targeting Dysbiosis for the Treatment of Liver Disease
Anand, G. S., Zarrinpar, A., & Loomba, R. S. (2016) · Seminars in Liver Disease · doi:10.1055/s-0035-1571276 · Cited by 59
NLR and Intestinal Dysbiosis-Associated Inflammatory Illness: Drivers or Dampers?
Elias‐Oliveira, J., Leite, J. A., Pereira, Í. S., Guimarães, J. B., Manso, G. M. D. C., Silva, J. S., Tostes, R. C., & Carlos, D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01810 · Cited by 59
TLR9 in MAFLD and NASH: At the Intersection of Inflammation and Metabolism
Shepard, C. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.613639 · Cited by 62
Pharmacologic and Nonpharmacologic Therapies for the Gut Microbiota in Type 2 Diabetes
Caesar, R. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.01.007 · Cited by 57
NLRP6 in host defense and intestinal inflammation
Venuprasad, K., & Theiss, A. L. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109043 · Cited by 59
Exploring the Gut Microbiome in Myasthenia Gravis
Thye, A. Y.-K., Law, J. W., Tan, L. T., Thurairajasingam, S., Chan, K., Letchumanan, V., & Lee, L. (2022) · Nutrients · doi:10.3390/nu14081647 · Cited by 61
Directly targeting ASC by lonidamine alleviates inflammasome-driven diseases
Chen, C., Zhou, Y., Ning, X., Li, S., Xue, D., Wei, C., Zhu, Z., Sheng, L., Lu, B., Li, Y., et al. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02682-w · Cited by 59
Jayachandran, M., & Qu, S. (2023) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09843-z · Cited by 57
Hu, W., Gong, W., Yang, F., Cheng, R., Zhang, G., Gan, L., Zhu, Y., Qin, W., Gao, Y., Li, X., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113937 · Cited by 60
Early‐life influences on obesity: from preconception to adolescence
Wahlqvist, M. L., Krawetz, S. A., Rizzo, N., Domínguez-Bello, M. G., Szymanski, L. M., Barkin, S. L., Yatkine, A., Waterland, R. A., Mennella, J. A., Desai, M., et al. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12778 · Cited by 59
Role of Intestinal Microbiome in Lipid and Glucose Metabolism in Diabetes Mellitus
van Olden, C. C., Groen, A. K., & Nieuwdorp, M. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.03.008 · Cited by 61
Loss of HDAC6 alters gut microbiota and worsens obesity
Lieber, A. D., Beier, U. H., Xiao, H., Wilkins, B. J., Jiao, J., Li, X. S., Schugar, R. C., Strauch, C., Wang, Z., Brown, J. M., et al. (2018) · The FASEB Journal · doi:10.1096/fj.201701586r · Cited by 58
Alicka, M., & Marycz, K. (2018) · Stem Cells International · doi:10.1155/2018/4274361 · Cited by 59
de Souza, A. B., Chaud, M. V., & Santana, M. H. A. (2019) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2019.115001 · Cited by 57
Klingbeil, E. A., Cawthon, C. R., Kirkland, R. A., & Serre, C. B. D. L. (2019) · Nutrients · doi:10.3390/nu11112710 · Cited by 58
Role of the duodenal microbiota in functional dyspepsia
Brown, G., Hoedt, E. C., Keely, S., Shah, A., Walker, M. M., Holtmann, G., & Talley, N. J. (2022) · Neurogastroenterology & Motility · doi:10.1111/nmo.14372 · Cited by 58
Reprogramming of Hepatic Metabolism and Microenvironment in Nonalcoholic Steatohepatitis
Rui, L., & Lin, J. D. (2022) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-062220-105200 · Cited by 59
Shin, J., Lee, Y., Song, E., Lee, D., Jang, S.-Y., Byeon, H. R., Hong, M.-G., Lee, S., Kim, H., Seo, J., et al. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1123547 · Cited by 60
Thompson, K. N., Bonham, K. S., Ilott, N. E., Britton, G. J., Colmenero, P., Bullers, S. J., McIver, L. J., Ma, S., Nguyen, L. H., Filer, A. D., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abn4722 · Cited by 57
Insulin resistance in clinical and experimental alcoholic liver disease
Carr, R. M., & Correnti, J. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12787 · Cited by 57
Probiotic potential of lactic acid bacteria present in home made curd in southern India.
Ramadass, B., Chandragunasekaran, A. S., Chellappan, G., Rajaram, K., Ramamoorthi, G., & Ramakrishna, B. S. (2014) · Europe PMC (PubMed Central) · Cited by 56
Watkins, A. A., Yasuda, K., Wilson, G. E., Aprahamian, T. R., Xie, Y., Maganto-García, E., Shukla, P., Oberlander, L., Laskow, B., Menn‐Josephy, H., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402807 · Cited by 57
Immune and genetic gardening of the intestinal microbiome
Jacobs, J. P., & Braun, J. G. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.02.052 · Cited by 60
Shapiro, H., Suez, J., & Elinav, E. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12501 · Cited by 56
Self-citationZheng, Y., Wu, W., Hu, G., Qiu, L., Meng, S., Song, C., Fan, L., Zhao, Z., Bing, X., & Chen, J. (2018) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2018.03.040 · Cited by 56
Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis
Roza, M. A. D., Kai, L., Kam, J. W., Chan, Y. H., Kwek, A. B. E., Ang, T. L., & Hsiang, J. C. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i33.4933 · Cited by 56
Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies
Leylabadlo, H. E., Ghotaslou, R., Kafil, H. S., Feizabadi, M. M., Moaddab, S. Y., Farajnia, S., Sheykhsaran, E., Sanaie, S., Shanehbandi, D., & Baghi, H. B. (2019) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-019-03746-1 · Cited by 56
Seth, R. K., Kimono, D., Alhasson, F., Sarkar, S., Albadrani, M., Lasley, S. K., Horner, R., Janulewicz, P., Nagarkatti, M., Nagarkatti, P., et al. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.05.006 · Cited by 55
Takahashi, H., Kotani, K., Tanaka, K., Egucih, Y., & Anzai, K. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00588 · Cited by 55
Xu, M., Zhou, E. Y., & Shi, H. (2025) · Cells · doi:10.3390/cells14050384 · Cited by 58
Microbiota regulation of inflammatory bowel disease and colorectal cancer
Liu, Z., Cao, A., & Cong, Y. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.09.002 · Cited by 55
Caspases and inflammasomes in metabolic inflammation
Skeldon, A. M., Faraj, M., & Saleh, M. (2014) · Immunology and Cell Biology · doi:10.1038/icb.2014.5 · Cited by 55
Regulation of Metabolism: A Cross Talk Between Gut Microbiota and Its Human Host
Burcelin, R. (2012) · Physiology · doi:10.1152/physiol.00023.2012 · Cited by 57
Microbiota prevents cholesterol loss from the body by regulating host gene expression in mice
Zhong, C., Sun, W., Ma, Y., Zhu, H., Yang, P., Wei, H., Zeng, B., Zhang, Q., Liu, Y., Li, W., et al. (2015) · Scientific Reports · doi:10.1038/srep10512 · Cited by 57
Li, X., Lian, F., Liu, C., Hu, K., & Wang, X. (2015) · Scientific Reports · doi:10.1038/srep16774 · Cited by 55
The Microbiome: a Revolution in Treatment for Rheumatic Diseases?
Rosenbaum, J. T., & Asquith, M. J. (2016) · Current Rheumatology Reports · doi:10.1007/s11926-016-0614-8 · Cited by 57
Allen, L., Ramalingam, L., Menikdiwela, K. R., Scoggin, S. O., Shen, C., Tomison, M. D., Kaur, G., Dufour, J. M., Chung, E., Kalupahana, N. S., et al. (2017) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2017.07.003 · Cited by 55
Shen, T., Li, X., Loor, J. J., Zhu, Y., Du, X., Wang, X., Xing, D., Shi, Z., Fang, Z., Li, X., et al. (2019) · Journal of Dairy Science · doi:10.3168/jds.2019-16706 · Cited by 58
The role of the gut microbiome in cancer-related fatigue: pilot study on epigenetic mechanisms
Xiao, C., Fedirko, V., Beitler, J. J., Bai, J., Peng, G., Zhou, C., Gu, J., Zhao, H., Lin, I., Chico, C. E., et al. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-020-05820-3 · Cited by 56
Li, X., Wei, Z., Wang, X., Duan, F., Xiong, L., Li, J., Tian, J., Jia, L., & Gao, H. X. (2021) · Food Chemistry · doi:10.1016/j.foodchem.2021.129164 · Cited by 54
Xia, T., He, W., Luo, Z., Wang, K., & Tan, X. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.132256 · Cited by 54
Lipid metabolites as metabolic messengers in inter-organ communication
Liu, S., Alexander, R., & Lee, C. (2014) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2014.05.002 · Cited by 57
Deficiency of intestinal mucin-2 protects mice from diet-induced fatty liver disease and obesity
Hartmann, P., Seebauer, C. T., Mazagova, M., Horvath, A., Wang, L., Llorente, C., Varki, N. M., Brandl, K., Ho, S. B., & Schnabl, B. (2015) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00094.2015 · Cited by 56
Foodomics as part of the host-microbiota-exposome interplay
Putignani, L., & Dallapiccola, B. (2016) · Journal of Proteomics · doi:10.1016/j.jprot.2016.04.033 · Cited by 56
Reciprocal interactions between bile acids and gut microbiota in human liver diseases
Ikegami, T., & Honda, A. (2017) · Hepatology Research · doi:10.1111/hepr.13001 · Cited by 54
Lactobacillus reuteri DSM 17938 alleviates d-galactosamine-induced liver failure in rats
Jiang, H., Ren, Y., Wang, K., Wang, Q., Chen, X., Chen, L., Li, L., & Lv, L. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111000 · Cited by 54
The Built Environment Is a Microbial Wasteland
Gibbons, S. M. (2016) · mSystems · doi:10.1128/msystems.00033-16 · Cited by 56
The intestinal microbiome associated with lipid metabolism and obesity in humans and animals
Jian, Z., Zeng, L., Xu, T., Sun, S., Yan, S., Zhao, S., Su, Z., Ge, C., Zhang, Y., Jia, J., et al. (2022) · Journal of Applied Microbiology · doi:10.1111/jam.15740 · Cited by 55
Dua, A., KUMARI, R. R., Singh, M., Kumar, R., Pradeep, S., Ojesina, A. I., & Kumar, R. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1618275 · Cited by 53
Innate immune signaling and gut-liver interactions in non-alcoholic fatty liver disease.
Bieghs, V., & Trautwein, C. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2304-3881.2014.12.04 · Cited by 54
STK25 is a critical determinant in nonalcoholic steatohepatitis
Amrutkar, M., Chursa, U., Kern, M., Nuñez‐Durán, E., Ståhlman, M., Sütt, S., Borén, J., Johansson, B. R., Marschall, H., Blüher, M., et al. (2016) · The FASEB Journal · doi:10.1096/fj.201600562r · Cited by 54
NAFLD, Helicobacter species and the intestinal microbiome
Castaño‐Rodríguez, N., Mitchell, H. M., & Kaakoush, N. O. (2017) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2017.09.008 · Cited by 53
Chen, Y., Sun, H., Bai, Y., & Zhi, F. C. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.12.180 · Cited by 53
Effects of orange essential oil on intestinal microflora in mice
Lin, W., Zhang, Y., Fan, G., Ren, J., Zhang, L., & Pan, S. (2019) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.9629 · Cited by 53
Microbiota Contribute to Obesity-Related Increases in the Pulmonary Response to Ozone
Tashiro, H., Cho, Y., Kasahara, D. I., Brand, J. D., Bry, L., Yeliseyev, V., Abu-Ali, G., Huttenhower, C., & Shore, S. A. (2019) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2019-0144oc · Cited by 54
Jadhav, K. S., & Cohen, T. S. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.592157 · Cited by 55
Horne, R. G., Yu, Y., Zhang, R., Abdalqadir, N., Rossi, L., Surette, M. G., Sherman, P. M., & Adeli, K. (2020) · Nutrients · doi:10.3390/nu12113557 · Cited by 57
Okazaki, I., Noro, T., Tsutsui, N., Yamanouchi, E., Kuroda, H., Nakano, M., Yokomori, H., & Inagaki, Y. (2014) · Cancers · doi:10.3390/cancers6031220 · Cited by 55
Targeting Cell Death and Sterile Inflammation Loop for the Treatment of Nonalcoholic Steatohepatitis
Wree, A., Mehal, W. Z., & Feldstein, A. E. (2016) · Seminars in Liver Disease · doi:10.1055/s-0035-1571272 · Cited by 52
Self-citationThe Role of the Gut Microbiota in Sustained Weight Loss Following Roux-en-Y Gastric Bypass Surgery
Fouladi, F., Brooks, A. E., Fodor, A. A., Carroll, I. M., Bulik‐Sullivan, E. C., Tsilimigras, M. C. B., Sioda, M., & Steffen, K. J. (2019) · Obesity Surgery · doi:10.1007/s11695-018-03653-y · Cited by 55
The role of gut microbiota in liver disease development and treatment
Wang, L., & Wan, Y. Y. (2019) · Liver Research · doi:10.1016/j.livres.2019.02.001 · Cited by 53
Zheng, P., Li, Y., Wu, J., Zhang, H., Huang, Y., Tan, X., Pan, J., Duan, J., Liang, W., Yin, B., et al. (2020) · Advanced Science · doi:10.1002/advs.202001296 · Cited by 52
Zhou, J., Yu, Y., Ding, L., Xu, P., & Wang, Y. (2021) · Nutrients · doi:10.3390/nu13061950 · Cited by 51
Choi, K. J., Yoon, M. Y., Kim, J.-E., & Yoon, S. S. (2023) · Scientific Reports · doi:10.1038/s41598-023-41160-y · Cited by 51
Gut-liver axis: Pathophysiological concepts and medical perspective in chronic liver diseases
Rodrigues, S. G., der Merwe, V., Krag, A. A., & Wiest, R. (2024) · Seminars in Immunology · doi:10.1016/j.smim.2023.101859 · Cited by 51
Zuo, G., Chen, M., Zuo, Y., Liu, F., Yang, Y., Li, J., Zhou, X., Li, M.-H., Huang, J., Liu, Z., et al. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.3c04832 · Cited by 51
Gautam, A., D’Arpa, P., Donohue, D. E., Muhie, S. Y., Chakraborty, N., Luke, B. T., Grapov, D., Carroll, E. E., Meyerhoff, J. L., Hammamieh, R., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117092 · Cited by 52
Vivoli, E., Cappon, A., Milani, S., Piombanti, B., Provenzano, A., Novo, E., Masi, A., Navari, N., Narducci, R., Mannaioni, G., et al. (2016) · Clinical Science · doi:10.1042/cs20160400 · Cited by 51
Palmitic acid elicits hepatic stellate cell activation through inflammasomes and hedgehog signaling
Duan, N.-N., Liu, X.-J., & Wu, J. H. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.03.012 · Cited by 51
Tsai, M.-T., Chen, Y.-J., Chen, C., Tsai, M., Han, C., Chen, Y., Mersmann, H. J., & Ding, S. (2017) · Journal of Nutrition · doi:10.3945/jn.116.240358 · Cited by 51
Managing portal hypertension in patients with liver cirrhosis
Sauerbruch, T., Schierwagen, R., & Trebicka, J. (2018) · F1000Research · doi:10.12688/f1000research.13943.1 · Cited by 52
Sun, C., Zhang, C., Duan, J., Guan, X., Yang, H., Jiang, H., Hammock, B. D., Hwang, S. H., Zhou, Y., Guan, C., et al. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.12.131 · Cited by 51
Review article: emerging anti‐fibrotic therapies in the treatment of non‐alcoholic steatohepatitis
Noureddin, M., Anstee, Q. M., & Loomba, R. S. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13620 · Cited by 50
He, Q., Zhang, Y., Ma, D., Zhang, W., & Zhang, H. (2022) · European Journal of Nutrition · doi:10.1007/s00394-021-02764-0 · Cited by 50
The Gut Microbiome and Ferroptosis in MAFLD
Ji, J., Wu, L., Wei, J., Wu, J., & Guo, C. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00136 · Cited by 50
Shi, Z., Zhang, C., Lei, H., Chen, C., Cao, Z., Song, Y., Chen, G., Wu, F., Zhou, J., Lu, Y., et al. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c06212 · Cited by 51
Mao, X., Larsen, S. B., Zachariassen, L. F., Brunse, A., Adamberg, S., Castro-Mejía, J. L., Larsen, F., Adamberg, K., Nielsen, D. S., Hansen, A. K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49152-w · Cited by 50
Sharma, V., Garg, S., & Aġġarwal, S. (2013) · The Permanente Journal · doi:10.7812/tpp/12-144 · Cited by 50
Gut Microbiota of Nonalcoholic Fatty Liver Disease
Abdou, R., Zhu, L., Baker, R. D., & Baker, S. S. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4045-1 · Cited by 52
Presentation of hepatocellular antigens
Grakoui, A., & Crispe, I. N. (2016) · Cellular and Molecular Immunology · doi:10.1038/cmi.2015.109 · Cited by 51
Intestinal permeability in a patient with liver cirrhosis
Aguirre-Valádez, J., Rivera-Espinosa, L., Méndez-Guerrero, O., Chávez-Pacheco, J. L., Juárez, I. G., & Torre, A. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s115902 · Cited by 52
Metadata
- Authors
- Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., Camporez, J.-P., Shulman, G. I., Gordon, J. I., Hoffman, H. M., & Flavell, R. A.
- Affiliations
- Yale University (US)
- Washington University in St. Louis (US)
- Howard Hughes Medical Institute (US)
- University of California San Diego (US)
- Corresponding author
- Flavell, Richard A.
- ORCID
- Venue
- Nature
- Published
- 2012-02
- Volume
- 482
- Issue
- 7384
- Pages
- 179-185
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3276682
- OpenAlex
- W2144275312
- Cited by
- 2,435
- References
- 41
- Citations by year
- 2026: 83 · 2025: 103 · 2024: 137 · 2023: 165 · 2022: 158 · 2021: 182 · 2020: 215 · 2019: 188 · 2018: 197 · 2017: 184 · 2016: 172 · 2015: 195 · 2014: 181 · 2013: 185 · 2012: 85
- FWCI
- 154.13
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Crohn's and Colitis Foundation
- U.S. Public Health Service (K08A1085038)
- National Heart, Lung, and Blood Institute (T32HL007974)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK45735, R01-DK40936, R01DK040936, U24DK059635, R01DK076674, R24DK085638, P30DK045735)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, NLRP3 inflammasome, NLRP6 inflammasome, IL-18, gut dysbiosis, metabolic syndrome, obesity, hepatic steatosis, liver inflammation, TLR4, TLR9, TNF-α, Porphyromonadaceae, host-microbiota interactions, autoinflammatory disease
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, Animals, Carrier Proteins, Choline, Colon, Cytoskeletal Proteins, Disease Models, Animal, Fatty Liver, Inflammation, Male, Methionine, Mice, Inbred C57BL, Obesity, Receptors, Cell Surface, RNA, Ribosomal, 16S, Tumor Necrosis Factor-alpha, Disease Progression, Interleukin-18, Apoptosis Regulatory Proteins, Toll-Like Receptor 4, Toll-Like Receptor 9, Mice, CARD Signaling Adaptor Proteins, Metagenome, Inflammasomes, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
